Abstract 10P
Background
Engraftment of cancer cells to liver pre-metastatic niches requires complex interaction with liver sinusoidal endothelial cells (LSECs). Intracellular gap (iGap) formation in LSECs is caused by the destruction of fenestrae and appears under pathological conditions. Here, we aimed to explore the novel role of LSECs-iGap in liver metastasis of cancer cells.
Methods
Mouse models using acetaminophen (APAP) or thioacetamide (TAA) followed by intrasplenic injection of hepatocellular carcinoma (HCC) cell line, Hepa1-6 cells, to assess the LSECs-iGap formation. Functional effects of LSECs-iGap on cancer cells were analyzed using MMPs inducer, monocrotaline and inhibitor, doxycycline and MMP2/9 inhibitor. Morphological and molecular features of LSECs-iGap were examined using in vivo mouse models and in vitro co-culture system with electron microscopy, 3 dimensions tomographic reconstruction image (3D-TRI), RNA-sequencing, cytokine array and endothelial trans-endothelial migration assay. Biopsy specimens from 98 patients with HCC were statistically evaluated.
Results
APAP-induced liver injury and TAA-induced fibrotic liver resulted in LSECs-iGap formation, which positively correlated with increased numbers of metastatic foci after Hepa1-6 cells injection. In addition, Hepa1-6 cells induced IL-23-dependent TNF-α secretion by LSECs and triggered LSECs-iGap formation, toward which their processes protruded to transmigrate into the liver parenchyma. TNF-α caused depolymerization of F-actin and increased MMP9, ICAM1, and CXCLs expression in LSECs. Moreover, high expression of ICAM1 and MMP9 was significantly associated with intrahepatic metastasis and overall survival of patients with HCC. Blocking MMP9 activity by doxycycline or MMP-2/9 inhibitor eliminated LSECs-iGap formation and attenuated liver metastasis of Hepa1-6 cells.
Conclusions
This study revealed that cancer cells induced LSEC-iGap formation via pro-inflammatory paracrine mechanisms and proposed MMP9 as a novel target for blocking cancer cell metastasis to the liver.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H.H. Truong.
Funding
Japan Agency for Medical Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Spatially resolved transcriptome elucidates bidirectional tertiary lymphoid structure interacts with tumor microenvironment of non-small cell lung cancer
Presenter: Xin Zhao
Session: Poster session 09
5P - Tertiary lymphoid structures (TLS) presence and stromal blood vessels heterogeneity differentially influence recurrence, lymphovascular, and perineural invasion in breast cancer molecular subtypes
Presenter: Andrei Cosma
Session: Poster session 09
6P - Combined single-cell and spatially resolved mapping of the human lymph node ecosystem reveals fundamental principles of lymphoma tissue organization
Presenter: Daniel Hübschmann
Session: Poster session 09
7P - Engineered salmonella blocks cancer metastasis by activating NK cells in an IFN-γ-dependent manner
Presenter: JIANDONG HUANG
Session: Poster session 09
8P - Modulating tumor microenvironment using a VEGF active immunotherapeutic approach in gastrointestinal tumors: Beyond angiogenesis modulation
Presenter: Mónica Bequet-Romero
Session: Poster session 09
9P - Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model
Presenter: Giulia Mazzaschi
Session: Poster session 09
11P - Targeting stromal cells to reverse immune suppression in triple-negative breast cancer
Presenter: Julia Chen
Session: Poster session 09
12P - Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells
Presenter: Christine Schuberth-Wagner
Session: Poster session 09
13P - Disrupting the immunosuppressive tumor microenvironment using genetically engineered macrophages for triple-negative breast cancer therapy
Presenter: Sabrina Traxel
Session: Poster session 09
14P - Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Presenter: MIGUEL GALINDO CAMPOS
Session: Poster session 09